Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 2:15 p.m. PT. Rand Sutherland, MD, Chief Executive Officer, will deliver the presentation. A live webcast will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event, and a replay will be posted on the company website after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – UPB
In the Jan 5 session, UPB declined 3.47%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conferences | Neutral | +10.7% | Announcement of CEO participation in two December 2025 investor conferences. |
| Nov 05 | Earnings & pipeline | Positive | -4.3% | Q3 2025 results with positive Phase 2 CRSwNP data and solid cash runway. |
| Oct 31 | Investor events | Neutral | +0.3% | Planned CEO participation in three November 2025 healthcare investor events. |
| Sep 30 | Clinical data | Positive | +8.5% | Presentation of structural and mechanistic data supporting verekitug’s differentiated profile. |
| Sep 09 | Single conference | Neutral | -2.6% | Announcement of CEO fireside chat at Stifel 2025 Virtual Immunology Forum. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: positive clinical and earnings updates sometimes saw negative moves, while neutral conference participation occasionally coincided with notable gains.
Over the past few months, Upstream Bio has combined clinical progress with active investor outreach. Positive Phase 2 data for verekitug and mechanistic findings in respiratory disease were reported in early September 2025, followed by continued conference participation in September, October, and November 2025. Q3 2025 results on November 5, 2025 highlighted cash runway through 2027 and advancing Phase 2 programs. Today’s J.P. Morgan Healthcare Conference appearance extends this pattern of regular investor and scientific visibility rather than representing a new clinical data event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT.
A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay will be available on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
